Risperidone extended release - Rovi

Drug Profile

Risperidone extended release - Rovi

Alternative Names: DORIA®; Risperidona ISM®; Risperidone-ISM®

Latest Information Update: 29 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rovi
  • Class Antineoplastics; Antipsychotics; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Schizophrenia

Most Recent Events

  • 17 May 2018 Rovi Pharmaceuticals Laboratories plans a phase I trial for Schizophrenia in May 2018 , (NCT03527186)
  • 29 May 2017 No development reported - Phase-I for Schizophrenia in Spain, South Africa, Russia, Croatia (IM)
  • 09 May 2017 Phase-III clinical trials in Schizophrenia in USA (IM) (NCT03160521)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top